The two landmark trials on SGLT2 inhibitors on HFpEF, the EMPEROR-Preserved [29] and the DELIVER trial [31], examined the efficacy of empagliflozin and dapagliflozin, respectively, in patients with HFpEF irrespective of diabetes status. Here, SLC5A2 is linked to diabetes mellitus.